Teplizumab, sold under the brand name Tzield among others, is an anti-CD3 humanized monoclonal antibody and the first approved treatment indicated to delay the onset of stage 3 type1 diabetes in people living with stage 2 type1 diabetes.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.